The tumor-agnostic anticancer drug ‘Rozlytrek’ may now be prescribed in 5 tertiary hospitals in Korea.

According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) inhibitor Rozlytrek (entrectinib)’ has passed review of drug committees (DCs) at the Big 5 tertiary hospitals in Korea, - Samsung Medical Center, Seoul National University Hospital, Seoul, Asan Medical Center, Seoul St.Mary’s Hospital, and Sinchon Severance Hospital – and its prescription code has been inserted in medical institutions nationwide.

Rozlytrek was listed for reimbursement this April. It is currently reimbursed for first-line or higher treatment of adult and pediatric patients